News

A new liver cancer trial explores a “two-in-one" treatment approach

Providence Cancer Institute is enrolling patients with hepatocellular carcinoma in a trial of pumitamig, an investigational bispecific antibody.

Providence Cancer Institute secures three significant grants

Prestigious grants will help researchers pursue important cancer studies.

Providence delivers $400 million turnaround through the first half of 2026

With Q2 results, Providence surpasses more than a year of profitability, fueled by focused restructuring and operational improvements

Providence and Arizona State University receive Stand Up To Cancer grant to advance next-generation cancer immunotherapy

Grant‑funded collaboration focuses on mRNA vaccine technology to strengthen personalized T‑cell therapies for pancreatic cancer

Q&A: Meet one of the investigational drug pharmacists at Providence

An inside look at how a pharmacist at Providence Cancer Institute keeps clinical trials running safely, one dose at a time.

New T-cell therapy for KRAS G12D cancers

An expanded access program uses engineered T cells to target the KRAS G12D mutation in pancreatic, colorectal or other advanced cancers.

New pancreatic cancer treatment option after chemo

A new oral therapy is available for metastatic pancreatic cancer that has progressed after chemotherapy.

Providence names Brad Myers chief pharmacy officer

Brad Myers, PharmD, MBA, has been named Providence's new chief pharmacy officer.

Leadership, empowerment training key to addressing clinician burnout, Providence study shows

Providence study reveals clinician burnout can be successfully addressed with empowerment and well-being leadership development training.

Amanda Chawla to join Providence as chief supply chain officer

Amanda Chawla has been named as Providence's chief supply chain officer. Chawla will lead systemwide supply chain strategy and operations, helping strengthen resiliency and improve performance.

Providence nursing leader Mila Sprouse named to esteemed nursing fellowship

Mila Sprouse, chief nursing officer for the North Puget Sound service area, has been named a 2026 fellow with the American Academy of Nursing.

When standard treatment isn’t enough: A new study offers hope for people with triple-negative breast cancer

A new clinical trial is testing a promising drug combination that could improve survival for people whose cancer didn’t fully respond to standard treatment.

Hope comes in a clinical trial: Brad’s remarkable story

When Brad’s medullary thyroid cancer returned after a surgical procedure, he enrolled in a clinical trial. Now, his cancer is nearly undetectable.

Colonoscopies finding a high rate of early onset colorectal cancer, Providence study finds

Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma

PSNI collaborates with Seattle-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier

Providence's environmental stewardship efforts net Practice Greenhealth’s highest honor

Providence today received a Greenhealth Top Health System Award by Practice Greenhealth. The award is Practice Greenhealth’s highest honor for health systems.

Providence researchers head to Chicago for leading cancer conference

Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are helping shape the future of cancer care at the 2026 ASCO Annual Meeting in Chicago.

Providence study finds AI ambient listening tool modestly reduces documentation burden, improves provider efficiency

Published in JAMA Network Open, a new Providence study uses real-world data to show how AI ambient listening reduces documentation burden, improving efficiency and clinician focus on patient care.

Providence study finds low radiation exposure during TAVR procedures, offers reassurance for physicians considering cardiology

Radiation exposure during TAVR procedures was low overall across nearly 9,000 cases performed at Providence from 2018 to 2022, according to a new Providence study.